Neuroblastoma is a neural crest-derived embryonal tumour of the postganglionic sympathetic nervous system and a disease with several different chromosomal gains and losses, which include MYCN-amplified neuroblastoma on chromosome 2, deletions of parts of the chromosomes 1p and 11q, gain of parts of 17q and triploidy. Recently, activating mutations of the ALK (Anaplastic Lymphoma Kinase) RTK (Receptor Tyrosine Kinase) gene have been described in neuroblastoma. A meta-analysis of neuroblastoma cases revealed that ALK mutations (49 of 709 cases) in relation to genomic subtype were most frequently observed in MYCN amplified tumours (8.9%), correlating with a poor clinical outcome. MYCN proteins target proliferation and apoptotic pathways, and have an important role in the progression of neuroblastoma. Here, we show that both wild-type and gain-of-function mutants in ALK are able to stimulate transcription at the MYCN promoter and initiate mRNA transcription of the MYCN gene in both neuronal and neuroblastoma cell lines. Further, this stimulation of MYCN gene transcription and de novo MYCN protein expression is abrogated by specific ALK inhibitors, such as crizotinib (PF-2341066), NVP-TAE684, and by small interfering RNA to ALK resulting in a decrease in proliferation rate. Finally, co-transfection of ALK gain-of-function mutations together with MYCN leads to an increase in transformation potential. Taken together, our results indicate that ALK signalling regulates initiation of transcription of the MYCN gene providing a possible explanation for the poor clinical outcome observed when MYCN is amplified together with activated ALK.
INTRODUCTION
Neuroblastoma is a neural crest-derived embryonal tumour of the postganglionic sympathetic nervous system and accounts for B15% of all deaths due to paediatric tumours. 1, 2 Genetically, many cases of neuroblastoma show amplification of the MYCN gene (B24% of all cases), deletions of parts of the chromosomes 1p and 11q, gain of parts of 17q and triploidy. 1,3 --6 Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase (RTK) is mutated in both familial and somatic neuroblastoma. 7 --11 Moreover, these reports also indicated that downregulation or inhibition of ALK led to a marked decrease of cell proliferation, suggesting ALK as a critical factor in the initiation and progression of neuroblastoma. The ALK RTK was first described in the mid-nineties and aberrant ALK protein activity is now implicated in a range of nonhematopoietic, hematopoietic as well as neuroendocrine tumours (for a review see Palmer et al. 12 ). A recent meta-analysis of neuroblastoma has reported ALK gain-of-function mutations to be present at a frequency of 6.9% of investigated neuroblastoma tumours. Further, a comparison of the ALK mutation frequency in relation to genomic subtype revealed that ALK mutations were most frequently observed in MYCN amplified tumours (8.9%), correlating with a poor clinical outcome. 1 Neuroblastoma cell lines with amplification of MYCN show increased proliferation, downregulation of angiogenesis inhibitors, inhibition of terminal differentiation and increased invasive potential, 3,13 --15 although it has been proposed that MYCN amplification is unlikely to be the initial event of tumour formation. 16 Stability and degradation of MYCN protein has been suggested to be regulated by a complex signalling network, including a plethora of post-translational modifications, such as phosphorylation/dephosphorylation and ubiquitination summarized in Gustafson and Weiss, 17 (and references therein). For instance, phosphorylation at position Ser62 results in stabilisation of MYCN. 18 Phosphorylation at position Thr58 on MYCN is mediated by GSK3-b in complex with other proteins, such as Pin1, PP2A and Axin. 17, 19, 20 This interplay is complex, as phosphorylation of MYCN at Thr58 alone by GSK3-b leads to interaction with the E3 ligase Fbxw7, leading to ubiquitination and degradation of MYCN. This scenario has been suggested to occur at low levels of PI3-kinase activity. 21 Conversely, formation of an Aurora A, Fbxw7 and MYCN complex, results in abrogation of degradation thereby uncoupling MYCN stability from growth factor dependent signals. 21 In addition, PKB/Akt activates mTORC1, which downregulates PP2A and thereby inhibiting dephosphorylation of Thr58/Ser62-phosphorylated MYCN mediating increased stabilisation of MYCN. Interestingly, in the mouse TH-MYCN neuroblastoma model it has been shown that inhibition of PI3-kinase activity destabilises MYCN protein and blocks malignant progression in neuroblastoma. 22 The regulation of the complex signalling networks involved in MYCN protein degradation is far from clear, but PI3-kinase and its downstream targets appear to have a critical role in the expression and stability of MYCN in neuroblastoma.
Many RTKs exhibit the potential to activate both ERK and PI3-kinase upon ligand stimulation, or as a result of an activating mutation. 23, 24 We therefore wished to examine the hypothesis that activation of ALK signalling might influence MYCN in the context of neuroblastoma. Our observations indicate that ALK stimulates initiation of transcription of the MYCN gene. This is true for the stimulated wild-type ALK receptor as well as various activating ALK mutants, and can be abrogated upon treatment with specific ALK inhibitors, such as crizotinib (PF-2341066) and NVP-TAE684, in both neuronal cell lines and neuroblastoma cell lines. Stimulation of the ALK receptor leads to increased de novo MYCN protein expression, while downregulation or inhibition of ALK results in decreased expression of MYCN protein and proliferation of neuroblastoma tumour cell lines. Finally, in transformation assays we show that MYCN cooperates with ALK gain-of-function mutations to increase transformation. This has implications in the setting of neuroblastoma, where a constitutively active ALK would potentially result in an increase in MYCN mRNA, thereby contributing to disease progression.
RESULTS AND DISCUSSION
ALK expression regulates the MYCN promoter in PC12 cells We initially investigated whether the MYCN promoter could be regulated by human ALK RTK. For this we employed MYCNPluciferase 25 in PC12 cells co-transfected with human ALK RTK. We observed a fivefold increase of luciferase activity upon cotransfection the MYCNP-luciferase construct with wild-type ALK compared with cells transfected with the MYCNP-luciferase construct alone (Figure 1a) . Further, we observed that PC12 cells co-transfected with MYCNP-luciferase and wild-type ALK displayed a 2 --3 fold increased expression of the MYCNP-luciferase reporter upon stimulation with mAb46, an agonist ALK antibody ( Figure 1a ). To further investigate the MYCNP-luciferase in response to ALK activity we employed various ALK inhibitors, such as crizotinib (PF-2341066) and NVP-TAE684. Crizotinib is a small ALK and c-Met specific inhibitor, which has shown promising results in clinical trials for non-small-cell lung cancer and IMT patients.
26 --32 NVP-TAE684 is a highly specific inhibitor for ALK, 33 and was employed as a complementary inhibitor in these studies. Recently Li et al. 34 compared the efficacy of crizotinib with NVP-TAE684 in a NSCLC model and demonstrated that NVP-TAE684 is more potent than crizotinib in inhibiting EML4-ALK oncogenic functions in vitro and in vivo, However, NVP-TAE684 is not currently in clinical trial. Both inhibitors efficiently abrogate MYCNP-luciferase activity mediated by mAb activation of wildtype ALK (Figure 1a ). In addition, we also co-transfected MYCNPluciferase with two human ligand-independent activated ALK mutants, ALK F1174L and ALK R1275Q , which are suggested to drive transformation and progression of neuroblastoma. 1,8 --11,35,36 Treatment of transfected cells with crizotinib and NVP-TAE684-reduced MYCNP-luciferase activity fourfold in ALK R1275Q expressing cells. A more modest reduction in MYCNP-luciferase activity was observed in cells expressing the ALK F1174L mutant, consistent with our observations indicating that ALK F1174L is less sensitive to inhibition by crizotinib and NVP-TAE684 (Figure 1a) . 36 As control, parallel examination of ERK activity shows the ligand-independent activation of the ALK F1174L and ALK R1275Q mutants as compared with the wild-type ALK receptor, which requires stimulation by the mAb46 agonist antibody for activation and resultant phosphorylation of ERK (Figure 1b) . However, ERK phosphorylation was abrogated upon addition of either crizotinib or NVP-TAE684 (Figure 1b) . These results were confirmed in clonally-derived PC12 cells, which inducibly express wild-type or mutant ALK, allowing comparison of the activity of these mutants in a controlled manner. 35, 37 In agreement with our previous results we observed that PC12 cells expressing wild-type ALK displayed a fivefold increase in MYCNP-luciferase upon stimulation of ALK with mAb46 (Figure 1c ). PC12 clones expressing ALK gain-of-function human ALK F1174S and mouse ALK R1279Q (which is equivalent to the human ALK R1275Q mutation), also increased the expression of the MYCNPluciferase reporter 2 --3 fold. Treatment with crizotinib or with NVP-TAE684 resulted in a fivefold decrease in the transcription and translation of the MYCNP-luciferase reporter when compared with untreated cells (Figure 1c) . It is worth noting that both PC12 hALK F1174S and mALK R1279Q cell lines express low levels of mutant ALK in the absence of doxycycline induction, in keeping with the reduction of luciferase activity by crizotinib to levels comparable to PC12 cell clone expressing the wild-type hALK. Control PC12 cells did not show any change in MYCNP-luciferase activity on addition of mAb46, crizotinib or NVP-TAE684 (Figures 1a and c) . Taken together, these results implicate MYCN as a putative downstream target of the ALK RTK-mediated signalling and suggest that the effect of ALK activity on the MYCN promoter region may be of functional relevance in neuroblastoma.
ALK regulates the MYCN promoter in human neuroblastoma cell lines As ALK is able to induce MYCNP-luciferase expression in PC12 cells, we decided to investigate this further in the context of neuroblastoma. To achieve this we employed several neuroblastoma cell lines to explore if ALK is able to regulate the promoter of the MYCN gene in this context. The following neuroblastoma cell lines were used; CLB-GA (non-amplified MYCN, 1p deletion, 11q deletion, 17q gain, non-amplified ALK amplicon-containing an ALK R1275Q mutation), CLB-GE (MYCN amplified, 1p deletion, 17q gain, amplified ALK amplicon-containing an ALK F1174V mutation) and CLB-BAR (amplified MYCN/ALK, 1p deletion, 17q gain). 10, 38, 39 Although more relevant to neuroblastoma than the controlled PC12 experimental setup, analyses of ALK mutations in neuroblastoma cell lines present significant interpretation problems owing to their variable genetic background. For example, the CLB --BAR cell line contains an abnormally activated ALK protein, although no point mutations have been found in the kinase domain of the receptor in this line, suggesting that indirect mechanisms lead to ALK activation in some circumstances. 10 Transfection of MYCNP-luciferase into CLB-BAR, CLB-GA and CLB-GE cells results in an increase in luciferase activity in these lines (Figure 1d ). Cells were treated with either crizotinib or NVP-TAE684, leading to a reduction in MYCNP-luciferase activity between three to fivefold (Figure 1d ), levels comparable to those observed in the different PC12 expressing ALK variants (Figure 1c) . We also examined the neuroblastoma cell line IMR32 (MYCN-/exon 2 --4 ALK amplified, 1p deletion, 17q gain (Supplementary Figure 7) , 39 in which a modest (B40%) stimulation of relative luciferase activity increased was observed upon mAb46 stimulation. This increase in activity of the MYCNP-luciferase is blocked upon pretreatment with crizotinib, supporting our earlier results (Supplementary Figure 1) . Thus, in PC12 cells and neuroblastoma cell lines activation of ALK results in increased initiation of transcription activity of the upstream promoter region of the MYCN gene. --- wt cells were stimulated with 1 mg/ml of the activating mAb46 as indicated. 37, 48, 49 Cells were lysed in 120 ml cell culture lysis reagent (Promega, Madison, WI, USA), of which 20 ml were used for luciferase assay according to manufacturer's protocol (Promega). Samples were measured in a TD-20/20 turner design luminometer (Turner Designs, Sunnyvale, CA, USA). Each sample within an experiment was performed in triplicate and the experiment was carried out three times. Results are presented as relative luciferase activity where the negative control (PC12 cells transfected with MYCNP-luciferase) was set to 1 and all other samples were set relative to the negative control (*). White bars: untreated transfected cells; dotted bar: transfected cells stimulated with 1 mg/ml mAb46; black bars: transfected cells treated with crizotinib; hatched bars: transfected cells treated with NVP-TAE684. (b) Western blot analysis of PC12 cell lysates showing effective inhibition of ALK downstream signalling by crizotinib used in (a), indicated by phospho-specific-ERK immunoblotting (p-ERK). Briefly, precleared cell lysates from the transfected PC12 cells were analyzed on SDS --PAGE, followed by immunoblotting with the indicated antibodies. ALK downstream activation was detected by p-ERK (Cell Signaling Technology, Danvers, MA, USA) and pan-ERK (BD Transduction Laboratories, Franklin Lakes, NJ, USA) was used to show equal loading. The horseradish peroxidase coupled secondary antibodies goat anti-rabbit IgG and goat anti-mouse IgG were from Thermo Scientific, Waltham, MA, USA. Cell lysis, immunoprecipitation and immunoblotting were performed according to the protocols described in. 37 (c) Luciferase assay of ALK-expressing doxycyline-inducible PC12 cell lines transfected with MYCNP-luciferase and empty pGL2 vector as a control, respectively. Stable PC12 Tet-on clones expressing human or mouse pTTP-ALK mut were generated and grown as described previously. 37 2 Â 10 6 doxycycline-inducible hALK wt hALK F1174S and mALK R1279Q PC12 cell lines 35 were transfected with 1.6 mg of either pGL2 (ctrl) or MYCNP-luciferase, as described in (a). Cells were then serum starved, and induced to express ALK employing doxycycline as indicated. Inhibition of ALK activity was achieved by treatment with 250 nM crizotinib or 50 nM NVP-TAE684 for 24 h as indicated. Light grey bars: uninduced PC12 cell lines; white bars: doxycycline-induced ALK-expressing untreated PC12 cell lines; dotted bar: ALK-expressing PC12hALK wt cells stimulated with 1 mg/ml mAb46; black bars: cells treated with crizotinib; hatched bars: cells treated with NVP-TAE684. Each sample within an experiment was performed in triplicate and the experiment was carried out three times. The diagram shows relative luciferase activity, where uninduced samples transfected with MYCNP-luciferase were set to 1(*). (d) Luciferase assay of neuroblastoma cell lines transfected with MYCNP-luciferase or empty pGL2 vector as a control. Neuroblastoma cell lines CLB-GA, CLB-GE and CLB-BAR were grown as described. 10 2 Â 10 5 cells of the neuroblastoma cell lines were transfected with empty pGL2 (ctrl) or MYCNP-luciferase employing Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) according to manufacturer's protocol. Cells were then serum starved and ALK activity was inhibited by employing 250 nM crizotinib or 50 nM NVP-TAE684 for 24 h. White bars: untreated neuroblastoma cell lines; black bars: cells treated with crizotinib; hatched bars: cells treated with NVP-TAE684. Each sample within an experiment was performed in triplicate and the experiment was carried out three times. The diagram shows relative luciferase activity where untreated samples transfected with empty pGL2 vector were set to 1. Student's t-test for luciferase activity versus inhibitor treated cells, CLB-GA and -BAR, Po0.01, for CLB-GE, Po0.05. compared with unstimulated IMR32 cells. In agreement with regulation of MYCN by ALK signalling, treatment of IMR32 cells with crizotinib or NVP-TAE684 before stimulation with mAb46 reduced the production of MYCN mRNA to levels comparable to non-treated IMR32 cells (Figure 2a) . Thus, pharmacological inhibition of ALK activity in neuroblastoma cell lines harbouring ALK gain-of-function mutations results in a reduced transcription of MYCN mRNA. Similarly, the IMR32 cell line, which contains no ALK mutation but is MYCN/ALK amplified, can upon stimulation produce increased levels of MYCN mRNA, which are abrogated by treatment with crizotinib or NVP-TAE684. Levels of up to 500 nM crizotinib are nontoxic for ALK-expressing PC12 cells for 24 h (data not shown). Proliferation of CLB-GA, CLB-GE and CLB-BAR cell lines was clearly inhibited by either 250 nM crizotinib or 50 nM NVP-TAE684 (Figures 2b-d; Supplementary Figure 6B ). In comparison, growth of IMR32 was modestly inhibited by 250 nM crizotinib, suggesting that these cells are not as dependent on ALK activity. However, treatment of IMR32 cells with higher doses of crizotinib (500 nM) clearly inhibited proliferation (Figure 2e ). These results further reinforce the hypothesis that ALK might be a driving force of cell proliferation and influence MYCN expression.
ALK activity drives MYCN protein expression We then wished to investigate protein levels of MYCN in human neuroblastoma cell lines. MYCN is expressed in CLB-GE, CLB-BAR and IMR32 (Figure 3) . However, to observe MYCN in the CLB-GA cell line, a non-amplified MYCN cell line, twice as much cell protein lysate was loaded as compared with other cell lines. Upon treatment with crizotinib (or NVP-TAE684, data not shown) for 48 h MYCN protein levels were reduced dramatically in all neuroblastoma cell lines (Figures 3a-c, compare lane 1 with 2) . To verify that crizotinib is abrogating the gain-of-function ALK activity we employed an antibody recognising the autophosphorylation of amino acid Tyr-1278 of ALK. Tyrosine 1278 of ALK is the first tyrosine of the Y'RAS'YY motif that is necessary for the 10 and IMR32 were starved and treated with 250 nM crizotinib (for IMR32, 500 nM), 50 nM NVP-TAE684 or 1 mg/ml mAb46 for 24 h as indicated. RNA was isolated with the NucleoSpin RNA II Kit (Macherey-Nagel, Duren, Germany). 1 mg of total RNA was reverse-transcribed using iScript cDNA Synthesis Kit (Bio-Rad, Sundbyberg, Sweden). For the PCR amplification in an iCycler iQ5 (Bio-Rad) 25 ng cDNA were used in a total reaction mix of 20 ml containing 10 ml Quantimix Easy SYG Kit (Biotools, Madrid, Spain), 250 nM of forward and reverse primer and 0.08 ml Fluorescein (USB (Affimetrix), Santa Clara, CA, USA). Primers amplifying part of the coding sequence of the ribosomal protein 29 (RPL29) were used to control for differences in cDNA input. The following primers were used: rat MYCN (forward autoactivation of the ALK kinase domain and the transformation ability of NPM-ALK. 40 In response to treatment with crizotinib tyrosine phosphorylation of Y1278 was clearly abrogated (Figures  3a-c, lane 2) . We observed identical results when employing NVP-TAE684 as inhibitor (data not shown).
Upon activation of IMR32 cells (wild-type ALK) with mAb for 48 h a modest increase in MYCN protein level could be detected (Figure 3d ). This observed increase in MYCN expression was reduced upon pretreatment of IMR32 cells with crizotinib ( Figure 3d ). Efficient inhibition of ALK activity in IMR32 by crizotinib was confirmed by loss of Y1278 phosphorylation. This supports our earlier observations that ALK is indeed active in the IMR32 cell line and that this activity contributes to MYCN levels in these cells. It has been suggested that high levels of MYCN directly or indirectly enhance expression of Aurora kinase A mRNA and that over expression of MYCN in SH-EP cells increases Aurora kinase A expression. 21, 41 Therefore, if ALK regulates initiation of transcription of MYCN we may expect to see changes in Aurora kinase A expression. Upon treatment with crizotinib a clear downregulation of expression of Aurora kinase A was observed in all neuroblastoma cell lines (Figures 3a-c, lane 2) , which is in agreement with earlier observations. 21, 41 Further, we also observed that inhibition of ALK reduced the phosphorylation/ activation of both PKB/Akt and ERK, indicating that ALK have the ability to mediate activation/phosphorylation of ERK and PKB in these cell lines. As control we treated the neuroblastoma cell lines with LY294002 and U0126 inhibitors, which inhibit PBK and ERK activity, respectively. We observed that abrogation of PKB and ERK activity reduces MYCN expression levels, without reducing the levels of ERK (Figures 3a-c, lane 3 and 4) or PKB proteins (data not shown). In the IMR32 neuroblastoma cell line ERK inhibition did not strongly inhibit MYCN expression (Figure 3d, lane 5) . Previous reports have indicated that inhibition of PI3K pathway influences both MYCN expression and stability in a mouse model. 22 MYCN stability is complex and incompletely understood 17, 21, 22, 42, 43 (and references therein). Our results are in agreement with role for ALK in regulating levels of MYCN in neuroblastoma cells.
Cycloheximide treatment abrogates MYCN protein translation, but not MYCN mRNA MYCN protein has a short half-life thus we employed cycloheximide, which is an effective inhibitor of protein biosynthesis. 44 To directly address the effect of ALK on the expression of MYCN protein the neuroblastoma cell lines CLB-GE, CLB-BAR and CLB-GA were treated with cycloheximide and harvested at the time points shown (Figure 4a ). The cell lines CLB-GE and CLB-BAR responded in a similar manner and less MYCN protein was observed after 2.5 h treatment of cycloheximide (Figure 4a) , which is comparable with previous reports. 22 The decrease in CLB-GA was not as clear, which may reflect the lack of MYCN amplification in this cell line, in contrast to the other neuroblastoma cell lines employed. However, no decrease of de novo MYCN mRNA transcription was observed during the treatment of cycloheximide using qRT --PCR analyses including two controls for differences in cDNA input (Figure 4b and Supplementary Figure 3) . Further, treatment of the neuroblastoma cells with the proteosome inhibitor, MG-132, 45 leads to high expression levels of MYCN within the cell (Figure 4c) . However, cells treated with crizotinib before treatment with MG-132 exhibit very low expression of MYCN compared with treatment with only MG-132, in agreement with our hypothesis that ALK activity drives initiation of transcription of MYCN (Figure 4c ). Taken together, we observe that ALK activation affects MYCN mRNA transcription in neuroblastoma cell lines.
Loss of ALK reduces cell growth, survival and MYCN protein expression Thus, far we have shown that ALK stimulates the MYCN transcription, an effect that is abrogated by treatment of neuroblastoma cells with crizotinib or NVP-TAE684 (Figures 2b-e  and 3 ). Inhibition of ALK activity by small interfering RNA (siRNA) was also employed in CLB-GA, -GE and -BAR neuroblastoma cell lines. Cells were transiently transfected with two independent siRNAs targeting either ALK or control scrambled siRNA. 3 NIH3T3 cells were transfected as previous described, 35 with 600 ng of indicated plasmids. 250 ng of pCDNA3-hALK wt , hALK F1174L or ALK R1275Q were combined with 350 ng pCDNA3-hMYCN cDNA or pCDNA3 as indicated. Plates were stained with crystal violet and QuantityOne (Bio-Rad) was used for densitometry analysis of formed foci. Bars represent average ± s.d. density of foci from three independent transfections. Student's t-test:
were reduced in all cell lines tested, compared with cells transfected with control siRNA or mock transfected cells (Figure 4e ). Further, knock down of ALK resulted in a significant decrease in cell number, B50% as compared with siRNA control transfected cells (Figure 4d ). In agreement with these results, downregulation of ALK by siRNA in neuroblastoma cell lines showed a 3 --4-fold (CLB-GA), 2 --3-fold (CLB-GE) and 2-fold (CLB-BAR) reduction in MYCN mRNA compared with non-treated cells (Supplementary Figure 4) and ALK R1275Q mutants exhibit ligand-independent signalling activity both in cell culture systems and in the Drosophila model system. 35, 36 Given the effect of ALK activity on MYCN transcription we wished to examine whether ALK and MYCN function together to drive cell transformation in NIH3T3 cells. Expression of either human ALK F1174L or ALK R1275Q mediate a robust transformation of NIH3T3 cells, whereas MYCN alone, or wild-type human ALK receptor with or without MYCN were unable to transform cells (Figure 4f, Supplementary Figure 5) . 35 In contrast, co-transfection of ALK F1174L together with MYCN results in a robust threefold increase in transformation when compared with activated ALK F1174L alone (Figure 4f, Supplementary Figure 5 ). Similar results were observed with ALK R1275Q together with MYCN ( Figure 4f ). In addition, we consistently observe that ALK F1174L possesses a stronger transforming potential as compared with ALK R1275Q in agreement with earlier observations. 36 Thus, expression of MYCN together with activating variants of ALK results in a more potent transforming effect.
In this study, we show that activation of ALK, either by stimulation of the wild-type ALK receptor or by gain-of-function ALK mutants activates initiation of MYCN mRNA transcription. Second, inhibition of ALK activity either by crizotinib or by siRNA targeting ALK results in decreased de novo MYCN protein expression levels as well as reduced proliferation of neuroblastoma cell lines. Cellular levels of MYCN protein within the cell are also dependent on complex regulation of stability versus degradation of MYCN proteins. 17, 22 Our data clearly indicate that ALK drives initiation of MYCN transcription. Finally, co-expression of constitutively active ALK mutants together with MYCN results in increased transforming potential. Our results strengthen the hypothesis that ALK provides a significant driving force for the development and onset of neuroblastoma as well as progression of the disease. Taken together with other recent reports showing ALK as an important factor in neuroblastoma these results would suggest that targeting ALK in neuroblastoma may be a successful weapon in the arsenal required to attack this disease. Indeed, Crizotinib, a small-molecule inhibitor targeting both c-Met and ALK, has already shown promising clinical effects in non-small-cell lung cancer, inflammatory myofibroblastic tumour and anaplastic large cell lymphoma, 26 --28,30,32 providing great hope for neuroblastoma patients harbouring ALK defects. The c-Met RTK has also been implicated in tumour progression. This is a valid concern, given that crizotinib also inhibits c-Met activity. Thus, we have employed a number of approaches to exclude a role for c-Met in the regulation of MYCN observed in these experiments. This has included the use of the c-Met inhibitor PHA665752, 46 as well as parallel studies with the more ALK-specific NVP-TAE684 inhibitor. Although robust effects on growth and proliferation were seen with crizotinib and NVP-TAE684, we were unable to observe any effect on growth or proliferation of our cell lines upon c-Met inhibition (Supplementary Figure 6B) . Further, stimulation of CLB-BAR and CLB-GE with hepatocyte growth factor, which is a ligand for c-Met was unable drive phosphorylation of downstream target molecules, such as ERK (Supplementary Figure 6A) . In agreement with these results, we did not detect either c-Met or the activated phospho-Met in these cell lines, whereas in control HeLa cells a robust activation of c-Met was observed. In HeLa cell controls, c-Met activation was efficiently abrogated by addition of PHA665752 indicating that the inhibition of c-Met is effective in these experiments (Supplementary Figure 6A) . Taken together these results indicate that while crizotinib is able to inhibit c-Met, this is not of functional importance in this study.
The finding that co-expression of the constitutively active ALK mutants and MYCN results in increased transformation as compared with MYCN, ALK F1174L or ALK R1275Q alone supports the hypothesis that ALK is one component responsible for increased MYCN protein levels. This may be of relevance for patients with chromosome 2 amplification harbouring either wild-type ALK or activating ALK variant, which show extremely poor clinical outcome. This is supported by discussions that there is a strong correlation between ALK immune reactivity with MYCN gene amplification, as well as between ALK protein expression and MYCN protein levels. 47 In summary, this study clearly shows that ALK activity regulates MYCN transcription and resultant protein levels in neuroblastoma cell lines. More importantly, MYCN expression can be reduced by inhibiting the activity of ALK, suggesting a promising therapeutic approach for the treatment of neuroblastoma patients harbouring MYCN and ALK genes amplification or ALK mutations.
